Quite interestingly, convergence of the p53 and RTK-RAS pathways in the regulation of cellular fate has been known for years [8]; however, our recent study—utilizing the extreme outlier methodology framework—is the first to assert its biologic relevance in the clinical arena in CRC patients. This evidence concerns the gene TP53 and colorectal carcinoma.